New drug combo aims to stop aggressive salivary cancer from coming back
NCT ID NCT06348264
Summary
This study is testing whether adding a new drug called rezvilutamide to standard hormone-blocking therapy can help prevent cancer from returning in people with a high-risk type of salivary gland cancer. It is for patients who have already had surgery and radiation, but whose cancer is likely to come back. The goal is to see if this two-year treatment plan improves survival by keeping the cancer away longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND NEOPLASM DUCT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University School and Hospital of Stomatology
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.